国药股份
(600511)
| 流通市值：163.62亿 | | | 总市值：223.11亿 |
| 流通股本：5.53亿 | | | 总股本：7.55亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 39,381,301,380.27 | 25,633,950,652.46 | 12,713,002,292.38 | 50,597,449,788.57 |
| 营业收入 | 39,381,301,380.27 | 25,633,950,652.46 | 12,713,002,292.38 | 50,597,449,788.57 |
| 二、营业总成本 | 37,808,187,653.76 | 24,641,402,034.11 | 12,193,672,811.38 | 48,403,886,743.93 |
| 营业成本 | 36,882,467,060.97 | 24,060,477,733 | 11,910,228,293.74 | 47,002,226,101.21 |
| 税金及附加 | 103,950,143.4 | 57,928,864.03 | 26,873,008.77 | 129,311,673.71 |
| 销售费用 | 491,126,559.53 | 306,056,493.15 | 152,279,509.46 | 805,142,288.61 |
| 管理费用 | 303,628,278.73 | 201,381,582.3 | 97,540,087.04 | 461,529,436.04 |
| 研发费用 | 43,593,756.03 | 28,015,746.87 | 13,814,602.47 | 73,707,682.75 |
| 财务费用 | -16,578,144.9 | -12,458,385.24 | -7,062,690.1 | -68,030,438.39 |
| 其中:利息费用 | 20,164,157.8 | 14,966,586.59 | 9,909,832.4 | 33,655,840.77 |
| 其中:利息收入 | 44,555,075.23 | 34,616,570.96 | 17,070,631.25 | 106,782,108.84 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -18,201,818.94 |
| 加:投资收益 | 440,990,983.15 | 293,601,361.38 | 116,029,603.74 | 514,166,266.66 |
| 资产处置收益 | 436,715.7 | 548.56 | -45,796.64 | -186,992.44 |
| 资产减值损失(新) | -9,922,046.21 | -8,207,322.15 | -5,876,575.91 | -1,066,320.03 |
| 信用减值损失(新) | -65,104,303.82 | -53,274,589 | -31,224,973.26 | -22,820,890.12 |
| 其他收益 | 6,020,672.59 | 4,450,139.07 | 2,448,012.1 | 11,968,624.68 |
| 四、营业利润 | 1,945,535,747.92 | 1,229,118,756.21 | 600,659,751.03 | 2,677,421,914.45 |
| 加:营业外收入 | 6,373,388.24 | 5,575,244.36 | 5,297,373.84 | 1,887,414.22 |
| 减:营业外支出 | 18,166,671.03 | 8,114,068.54 | 79,859.24 | 25,696,937.17 |
| 五、利润总额 | 1,933,742,465.13 | 1,226,579,932.03 | 605,877,265.63 | 2,653,612,391.5 |
| 减:所得税费用 | 377,847,999.35 | 235,096,525.17 | 120,816,068.97 | 523,831,826.46 |
| 六、净利润 | 1,555,894,465.78 | 991,483,406.86 | 485,061,196.66 | 2,129,780,565.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,555,894,465.78 | 991,483,406.86 | 485,061,196.66 | 2,129,780,565.04 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,492,265,301.07 | 948,547,379.33 | 459,015,386.52 | 2,000,126,943.49 |
| 少数股东损益 | 63,629,164.71 | 42,936,027.53 | 26,045,810.14 | 129,653,621.55 |
| 扣除非经常损益后的净利润 | 1,470,144,060.96 | 931,500,919.48 | 446,230,701.31 | 1,996,141,089.85 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.98 | 1.26 | 0.61 | 2.65 |
| (二)稀释每股收益 | 1.98 | 1.26 | 0.61 | 2.65 |
| 八、其他综合收益 | 25,861,163.15 | 337,686.56 | -84,421.65 | -3,461,287.34 |
| 归属于母公司股东的其他综合收益 | 25,861,163.15 | 337,686.56 | -84,421.65 | -3,461,287.34 |
| 九、综合收益总额 | 1,581,755,628.93 | 991,821,093.42 | 484,976,775.01 | 2,126,319,277.7 |
| 归属于母公司股东的综合收益总额 | 1,518,126,464.22 | 948,885,065.89 | 458,930,964.87 | 1,996,665,656.15 |
| 归属于少数股东的综合收益总额 | 63,629,164.71 | 42,936,027.53 | 26,045,810.14 | 129,653,621.55 |
| 公告日期 | 2025-10-22 | 2025-08-21 | 2025-04-25 | 2025-03-20 |
| 审计意见(境内) | | | | 标准无保留意见 |